Temsirolimus mTOR inhibitor  

CCI-779 - CCI 779 - Torisel      

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

advanced breast cancer (metastatic)  

HORIZON, 2013      NCTtemsirolimus + letrozoleletrozole alone 1st line HR positive postmenopausal Low risk of bias negative-10%-11%

renal-cell carcinoma (advanced)  

ARCC (Hudes) temsirolimus alone, 2007      NCTtemsirolimusinterferon alphasuggesting-27%
INTORSECT, 2014      NCTtemsirolimussorafenibnegative -13%31%